IPSEN (OTCMKTS:IPSEY) Short Interest Update

IPSEN (OTCMKTS:IPSEY) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 268 shares, an increase of 87.4% from the June 15th total of 143 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,589 shares, the short-interest ratio is currently 0.2 days.

IPSEN Price Performance

Shares of IPSEN stock remained flat at $44.07 on Friday. 76 shares of the stock traded hands, compared to its average volume of 750. IPSEN has a 1-year low of $30.05 and a 1-year high of $51.10. The firm has a 50-day moving average of $46.64 and a 200-day moving average of $44.82.

Analyst Ratings Changes

IPSEY has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).